These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 1411620

  • 1. Carboplatin/cyclophosphamide combination chemotherapy for advanced ovarian cancer.
    Teeling M, Hayes Y, Fitzmaurice B, McGing P, Carney DN.
    Semin Oncol; 1992 Feb; 19(1 Suppl 2):102-6. PubMed ID: 1411620
    [Abstract] [Full Text] [Related]

  • 2. Phase II study of carboplatin and cyclophosphamide combination chemotherapy for the treatment of advanced ovarian cancer.
    Teeling M, Carney DN.
    Eur J Gynaecol Oncol; 1990 Feb; 11(3):219-24. PubMed ID: 2209642
    [Abstract] [Full Text] [Related]

  • 3. Results of a Southwest Oncology Group phase III trial of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide in advanced ovarian cancer.
    Hannigan EV, Green S, Alberts DS, O'Toole R, Surwit E.
    Oncology; 1993 Nov; 50 Suppl 2():2-9. PubMed ID: 8233297
    [Abstract] [Full Text] [Related]

  • 4. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
    Tung N, Berkowitz R, Matulonis U, Quartulli M, Seiden M, Kim Y, Niloff J, Cannistra SA.
    Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
    Pujade-Lauraine E, Guastalla JP, Weber B, Curé H, Orfeuvre H, Mousseau M, Vincent P, Diéras V, Tubiana-Mathieu N, Jacquin JP, Mignot L, Leduc B, Paraïso D, Viens P.
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
    [Abstract] [Full Text] [Related]

  • 6. Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer.
    Anderson H, Wagstaff J, Crowther D, Swindell R, Lind MJ, McGregor J, Timms MS, Brown D, Palmer P.
    Eur J Cancer Clin Oncol; 1988 Sep; 24(9):1471-9. PubMed ID: 3053207
    [Abstract] [Full Text] [Related]

  • 7. Cisplatin, carboplatin, and cyclophosphamide combination chemotherapy in advanced-stage ovarian carcinoma: an Eastern Cooperative Oncology Group pilot study.
    Grem J, O'Dwyer P, Elson P, Simon N, Trump D, Frontiera M, Falkson G, Vogl S.
    J Clin Oncol; 1991 Oct; 9(10):1793-800. PubMed ID: 1919629
    [Abstract] [Full Text] [Related]

  • 8. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
    Harper P.
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
    [Abstract] [Full Text] [Related]

  • 9. Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial.
    Paccagnella A, Favaretto A, Oniga F, Festi G, Lauro S, Morabito A, Ossana L, Sartore F, DePoli F, Fiorentino MV.
    Cancer; 1996 Oct 15; 78(8):1701-7. PubMed ID: 8859183
    [Abstract] [Full Text] [Related]

  • 10. Dose intensification of platinum compounds with glutathione protection as induction chemotherapy for advanced ovarian carcinoma.
    Böhm S, Oriana S, Spatti G, Di Re F, Breasciani G, Pirovano C, Grosso I, Martini C, Caraceni A, Pilotti S, Zunino F.
    Oncology; 1999 Oct 15; 57(2):115-20. PubMed ID: 10461057
    [Abstract] [Full Text] [Related]

  • 11. A phase II study of carboplatin and cyclophosphamide in advanced ovarian carcinoma.
    Martoni A, Panetta A, Angelelli B, Melotti B, Pannuti F.
    J Chemother; 1993 Feb 15; 5(1):47-51. PubMed ID: 8459265
    [Abstract] [Full Text] [Related]

  • 12. Carboplatin in combination with epirubicin and cyclophosphamide in patients with advanced ovarian cancer. A phase II study.
    Andersson H, Friberg LG, Horvath G, Johansson O, Akesson M, Westberg R.
    Acta Oncol; 1995 Feb 15; 34(6):821-7. PubMed ID: 7576751
    [Abstract] [Full Text] [Related]

  • 13. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer.
    Alberts DS, Green S, Hannigan EV, O'Toole R, Stock-Novack D, Anderson P, Surwit EA, Malvlya VK, Nahhas WA, Jolles CJ.
    J Clin Oncol; 1992 May 15; 10(5):706-17. PubMed ID: 1569443
    [Abstract] [Full Text] [Related]

  • 14. [Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer].
    Meng LH, Kong BH, Zhang YZ, Yang XS, Wang LJ, Su SL, Jiang J, Cui BX, Wang B.
    Zhonghua Fu Chan Ke Za Zhi; 2007 Oct 15; 42(10):683-7. PubMed ID: 18241544
    [Abstract] [Full Text] [Related]

  • 15. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
    Skarlos DV, Aravantinos G, Kosmidis P, Athanassiadis A, Stathopoulos GP, Pavlidis N, Bafaloukos D, Karphathios S, Papakostas P, Bamia C, Fountzilas G.
    Semin Oncol; 1997 Oct 15; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
    [Abstract] [Full Text] [Related]

  • 16. Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer.
    Shapiro JD, Rothenberg ML, Sarosy GA, Steinberg SM, Adamo DO, Reed E, Ozols RF, Kohn EC.
    Cancer; 1998 Nov 01; 83(9):1980-8. PubMed ID: 9806657
    [Abstract] [Full Text] [Related]

  • 17. A phase II study of carboplatin and cisplatin in advanced ovarian cancer.
    Segelov E, Stuart-Harris R, Bell D, Tattersall M, Hutton-Potts J, Friedlander M.
    Eur J Gynaecol Oncol; 1994 Nov 01; 15(4):277-82. PubMed ID: 7957335
    [Abstract] [Full Text] [Related]

  • 18. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis.
    Langer CJ, Leighton JC, Comis RL, O'Dwyer PJ, McAleer CA, Bonjo CA, Engstrom PF, Litwin S, Ozols RF.
    J Clin Oncol; 1995 Aug 01; 13(8):1860-70. PubMed ID: 7543559
    [Abstract] [Full Text] [Related]

  • 19. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.
    Gray HJ, Shah CA, Swensen RE, Tamimi HK, Goff BA.
    Gynecol Oncol; 2010 Mar 01; 116(3):340-4. PubMed ID: 19922987
    [Abstract] [Full Text] [Related]

  • 20. First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up.
    Fujiwara K, Sakuragi N, Suzuki S, Yoshida N, Maehata K, Nishiya M, Koshida T, Sawai H, Aotani E, Kohno I.
    Gynecol Oncol; 2003 Sep 01; 90(3):637-43. PubMed ID: 13678738
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.